Covered recipient · General Payments record
MARC PLISKIN
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$7,689.47
131 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,875.00 | 3 |
| Food and Beverage | $2,288.10 | 124 |
| Consulting Fee | $390.00 | 1 |
| Education | $122.93 | 2 |
| Travel and Lodging | $13.44 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Myovant Sciences Inc. | $5,214.63 | 17 |
| Janssen Scientific Affairs, LLC | $532.00 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $327.56 | 22 |
| Astellas Pharma US Inc | $293.60 | 15 |
| BOSTON SCIENTIFIC CORPORATION | $291.05 | 13 |
| COLOPLAST CORP | $159.19 | 13 |
| Merck Sharp & Dohme Corporation | $140.59 | 4 |
| AstraZeneca Pharmaceuticals LP | $136.05 | 4 |
| UROGEN PHARMA, INC. | $117.00 | 6 |
| Janssen Biotech, Inc. | $110.47 | 8 |
| Blue Earth Diagnostics Limited | $106.62 | 4 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $52.07 | 3 |
| Dendreon Pharmaceuticals LLC | $46.21 | 2 |
| Clarus Therapeutics Inc. | $39.91 | 4 |
| PFIZER INC. | $36.39 | 8 |
| TOLMAR Pharmaceuticals, Inc. | $31.57 | 2 |
| UROVANT SCIENCES INC | $15.48 | 1 |
| Endo Pharmaceuticals Inc. | $14.24 | 1 |
| PROCEPT BioRobotics Corporation | $12.95 | 1 |
| Mission Pharmacal Company | $11.89 | 1 |
Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARC PLISKIN
NPI 1174569362 · CMS profile ID 482227
Allopathic & Osteopathic Physicians / Urology
CINCINNATI, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1174569362?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARC PLISKIN, NPI 1174569362, CMS profile ID 482227. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174569362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). MARC PLISKIN, NPI 1174569362, CMS profile ID 482227. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174569362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- MARC PLISKIN, NPI 1174569362, CMS profile ID 482227, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1174569362?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
131 matching records · $7,689.47 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–131 of 131.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Myovant Sciences Inc. | $13.44 | 05/01/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834981489 | CMS |
| Myovant Sciences Inc. | $2,275.00 | 05/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834981493 | CMS |
| Myovant Sciences Inc. | $94.57 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834981485 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.25 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789129777 | CMS |
| Myovant Sciences Inc. | $12.93 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834981481 | CMS |
| Blue Earth Diagnostics Limited | $26.71 | 04/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 844629249 | CMS |
| AstraZeneca Pharmaceuticals LP | $92.48 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829580971 | CMS |
| Janssen Biotech, Inc. | $15.09 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787954703 | CMS |
| Mission Pharmacal Company | $11.89 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 754274684 | CMS |
| Myovant Sciences Inc. | $14.29 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834981477 | CMS |
| COLOPLAST CORP | $12.98 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844274155 | CMS |
| Clarus Therapeutics Inc. | $10.95 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855018941 | CMS |
| Astellas Pharma US Inc | $15.00 | 04/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821496787 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $5.28 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789038261 | CMS |
| Myovant Sciences Inc. | $23.93 | 03/31/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834981471 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $2.51 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789125867 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $10.99 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789199551 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $123.77 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789066763 | CMS |
| Janssen Biotech, Inc. | $17.67 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787954713 | CMS |
| Myovant Sciences Inc. | $1,300.00 | 03/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834981467 | CMS |
| UROGEN PHARMA, INC. | $5.98 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826686579 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.23 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789077817 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $2.14 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789086847 | CMS |
| BOSTON SCIENTIFIC CORPORATION | $21.61 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 777649509 | CMS |
| TOLMAR Pharmaceuticals, Inc. | $15.44 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836489403 | CMS |
| Astellas Pharma US Inc | $15.18 | 02/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821496781 | CMS |
| Astellas Pharma US Inc | $17.62 | 02/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821496775 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.24 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830088445 | CMS |
| Myovant Sciences Inc. | $14.54 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834981463 | CMS |
| COLOPLAST CORP | $10.66 | 01/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844274131 | CMS |
| Astellas Pharma US Inc | $10.08 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821496769 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $5,330.00 | 2 |
| PY2025 | Principal investigator | $3,519,210.09 | 271 |
| PY2024 | Recipient | $5,080.00 | 3 |
| PY2024 | Principal investigator | $3,563,367.29 | 325 |
| PY2023 | Recipient | $990.00 | 3 |
| PY2023 | Principal investigator | $2,312,524.64 | 348 |
| PY2022 | Recipient | $1,749.00 | 1 |
| PY2022 | Principal investigator | $2,820,009.44 | 141 |
| PY2021 | Principal investigator | $3,126,903.15 | 111 |
| PY2020 | Principal investigator | $3,375,899.80 | 350 |
| PY2019 | Principal investigator | $1,945,683.92 | 262 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
273 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,129.43 | 12/31/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc. dba The Urology Group | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett | No dispute reported | 06/30/2026 | 1232924970 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,491.28 | 12/31/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc. dba The Urology Group | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926973 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $9,857.91 | 12/31/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc. dba The Urology Group | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 | No dispute reported | 06/30/2026 | 1232927931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,033.00 | 12/26/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395598 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,572.00 | 12/25/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $41,500.00 | 12/25/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) | No dispute reported | 06/30/2026 | 1175395699 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 12/25/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811518 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 12/25/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811523 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $56.54 | 12/19/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401697 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $430.67 | 12/19/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401705 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 12/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401689 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 12/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401691 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 12/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401693 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 12/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401699 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 12/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401701 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 12/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401707 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/12/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228706751 |
| Principal investigator 1 | MEDIVATION LLC. | $264.60 | 12/11/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811448 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 12/11/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811493 |
| Principal investigator 1 | COLOPLAST CORP | $3,495.15 | 12/09/2025 | Non-covered Recipient Entity The Urology Group | INTIBIA | No dispute reported | 06/30/2026 | 1226927246 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,847.00 | 12/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175395643 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,198.00 | 12/01/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395770 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $48,688.24 | 12/01/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc. dba The Urology Group | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926799 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 11/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401632 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 11/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401636 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $430.67 | 11/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401638 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 11/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401644 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 11/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401646 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,592.00 | 11/24/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175257301 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52,730.00 | 11/17/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395609 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 11/14/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401634 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 11/14/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401649 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $5,100.00 | 11/14/2025 | Non-covered Recipient Entity THE UROLOGY GROUP | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892647 |
| Principal investigator 1 | Janssen Research & Development, LLC | $44,341.00 | 11/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395603 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 11/10/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228803915 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 11/08/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228804060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,758.00 | 11/07/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175395637 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 11/07/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395731 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 11/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811966 |
| Recipient | PFIZER INC. | $330.00 | 11/03/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228803843 |
| Principal investigator 1 | PFIZER INC. | $869.88 | 10/29/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228825078 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $430.67 | 10/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401651 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 10/10/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228803923 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 10/09/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228803910 |
| Principal investigator 1 | PFIZER INC. | $21,499.00 | 10/08/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228825877 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 10/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395784 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,924.00 | 10/03/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175395766 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 10/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811442 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 10/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811453 |
| Principal investigator 1 | MEDIVATION LLC. | $12,657.48 | 10/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811956 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 10/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228811960 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $54.84 | 09/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45,838.00 | 09/29/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395759 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 09/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401673 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 09/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,075.00 | 09/19/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175256873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $303.00 | 09/19/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175256945 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 09/18/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401663 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $63.39 | 09/18/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401667 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $63.39 | 09/18/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401669 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 09/18/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401675 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 09/18/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401679 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 09/17/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401665 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 09/17/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401671 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,155.19 | 09/17/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401681 |
| Principal investigator 1 | Janssen Research & Development, LLC | $67,716.00 | 09/15/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395631 |
| Principal investigator 1 | COLOPLAST CORP | $3,090.15 | 09/10/2025 | Non-covered Recipient Entity The Urology Group | INTIBIA | No dispute reported | 06/30/2026 | 1226927244 |
| Principal investigator 1 | Organon Llc | $600.00 | 09/10/2025 | Non-covered Recipient Entity Tristate Urologic Services PSC Inc | 3475-676 | No dispute reported | 06/30/2026 | 1173042188 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,018.00 | 09/09/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175256673 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/09/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc dba The Urology Group | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228718475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,409.00 | 09/08/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,264.00 | 09/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395660 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 09/04/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228834738 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $313.08 | 08/31/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc. dba The Urology Group | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926975 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/31/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc dba The Urology Group | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228717391 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401606 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,155.19 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401612 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401630 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,632.00 | 08/25/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395707 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 08/21/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228804065 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 08/20/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228804072 |
| Principal investigator 1 | PFIZER INC. | $869.88 | 08/14/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228844144 |
| Principal investigator 1 | COLOPLAST CORP | $1,545.08 | 08/13/2025 | Non-covered Recipient Entity The Urology Group | INTIBIA | No dispute reported | 06/30/2026 | 1226927242 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $5,000.00 | 08/11/2025 | Non-covered Recipient Entity THE UROLOGY GROUP | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892389 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,918.00 | 08/11/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395626 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $10,500.00 | 08/08/2025 | Non-covered Recipient Entity THE UROLOGY GROUP | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892352 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 08/07/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228834732 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 08/01/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401604 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 08/01/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401614 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 08/01/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401620 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,322.00 | 07/28/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175256983 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52,730.00 | 07/28/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395711 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/22/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228804029 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/21/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228803849 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,099.00 | 07/07/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395653 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,293.00 | 07/04/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395725 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 07/03/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228834688 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,585.00 | 06/25/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175256810 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,800.00 | 06/24/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175257074 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,972.00 | 06/24/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175257442 |
| Recipient | Dendreon Pharmaceuticals LLC | $5,000.00 | 06/09/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891635 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $5,000.00 | 06/09/2025 | Non-covered Recipient Entity THE UROLOGY GROUP | ProvONE | No dispute reported | 06/30/2026 | 1247892214 |
| Principal investigator 1 | Janssen Research & Development, LLC | $66,011.00 | 06/09/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395717 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,231.00 | 06/09/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395749 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 06/09/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc dba The Urology Group | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228823396 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 06/08/2025 | Non-covered Recipient Entity TriState urologic Services PSC Inc dba The Urology Group | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228834517 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 06/06/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401600 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,500.00 | 06/05/2025 | Non-covered Recipient Entity ADVANCED UROLOGY ASSOCIATES | ProvONE | No dispute reported | 06/30/2026 | 1247892188 |
| Principal investigator 1 | MEDIVATION LLC. | $264.60 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848949 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849477 |
| Principal investigator 1 | MEDIVATION LLC. | $264.60 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849522 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849549 |
| Principal investigator 1 | MEDIVATION LLC. | $264.60 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849555 |
| Principal investigator 1 | MEDIVATION LLC. | $264.60 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849601 |
| Principal investigator 1 | MEDIVATION LLC. | $1,188.00 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849858 |
| Principal investigator 1 | MEDIVATION LLC. | $264.60 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849874 |
| Principal investigator 1 | MEDIVATION LLC. | $264.60 | 06/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850235 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401582 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $430.67 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401590 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401596 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401598 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,222.00 | 06/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m | No dispute reported | 06/30/2026 | 1175395790 |
| Principal investigator 1 | PFIZER INC. | $1,767.48 | 05/24/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228856646 |
| Principal investigator 1 | PFIZER INC. | $92,412.24 | 05/23/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228841563 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 05/22/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401550 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $83.97 | 05/22/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401554 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 05/22/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401558 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 05/22/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401560 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 05/22/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401562 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 05/22/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401564 |
| Principal investigator 1 | PFIZER INC. | $92,415.78 | 05/22/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228834561 |
| Principal investigator 1 | PFIZER INC. | $92,412.24 | 05/22/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228841594 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 05/16/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401548 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 05/16/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401556 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 05/16/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401566 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,632.00 | 05/12/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395794 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 04/28/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395753 |
| Principal investigator 1 | Janssen Research & Development, LLC | $39,434.00 | 04/25/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395684 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 04/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401502 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 04/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,621.00 | 04/24/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175256991 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/23/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228841618 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 04/22/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228834528 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/22/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228841588 |
| Principal investigator 1 | MEDIVATION LLC. | $13,126.33 | 04/17/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848838 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848831 |
| Principal investigator 1 | MEDIVATION LLC. | $66.75 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848848 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848962 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848970 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848975 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848986 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228848992 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849064 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849070 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849078 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849085 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849366 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849404 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849412 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849414 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849461 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849470 |
| Principal investigator 1 | MEDIVATION LLC. | $66.75 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849530 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849539 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849561 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849589 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849596 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849610 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849665 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849671 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849678 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849726 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849742 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849779 |
| Principal investigator 1 | MEDIVATION LLC. | $66.75 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849785 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849792 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849866 |
| Principal investigator 1 | MEDIVATION LLC. | $66.75 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849938 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228849948 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850047 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850057 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850067 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850162 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850170 |
| Principal investigator 1 | MEDIVATION LLC. | $66.75 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850181 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850190 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850230 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850243 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850250 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850258 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850264 |
| Principal investigator 1 | MEDIVATION LLC. | $29.40 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850322 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850326 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850336 |
| Principal investigator 1 | MEDIVATION LLC. | $132.00 | 04/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850413 |
| Principal investigator 1 | PFIZER INC. | $9,610.92 | 04/08/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228860956 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,798.00 | 04/07/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395621 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 04/03/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395737 |
| Principal investigator 1 | MEDIVATION LLC. | $1,056.00 | 04/03/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228850150 |
| Principal investigator 1 | Janssen Research & Development, LLC | $87,820.00 | 03/27/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395743 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 03/25/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401460 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 03/25/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401510 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 03/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401504 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 03/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401508 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 03/24/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc dba The Urology Group | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228823480 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 03/23/2025 | Non-covered Recipient Entity TriState urologic Services PSC Inc dba The Urology Group | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228834567 |
| Principal investigator 1 | Janssen Research & Development, LLC | $60,130.00 | 03/21/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $905.00 | 03/17/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175257067 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 03/13/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401524 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,638.00 | 03/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395666 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,099.00 | 03/07/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395672 |
| Principal investigator 1 | MEDIVATION LLC. | $235.20 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228855503 |
| Principal investigator 1 | MEDIVATION LLC. | $235.20 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228855547 |
| Principal investigator 1 | MEDIVATION LLC. | $1,056.00 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228855559 |
| Principal investigator 1 | MEDIVATION LLC. | $235.20 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228855598 |
| Principal investigator 1 | MEDIVATION LLC. | $235.20 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228855609 |
| Principal investigator 1 | MEDIVATION LLC. | $235.20 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228856439 |
| Principal investigator 1 | MEDIVATION LLC. | $1,056.00 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228856446 |
| Principal investigator 1 | MEDIVATION LLC. | $534.00 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228856489 |
| Principal investigator 1 | MEDIVATION LLC. | $534.00 | 03/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228856498 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,116.20 | 03/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630192 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,119.00 | 03/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630196 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,500.00 | 03/05/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630292 |
| Principal investigator 1 | PFIZER INC. | $92,412.24 | 03/04/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228841581 |
| Principal investigator 1 | PFIZER INC. | $92,415.78 | 03/03/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228834522 |
| Principal investigator 1 | PFIZER INC. | $92,412.24 | 03/03/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228841606 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 02/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401506 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 02/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401450 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 02/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401544 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,420.00 | 02/26/2025 | Non-covered Recipient Entity THE UROLOGY GROUP | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891789 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $10,500.00 | 02/26/2025 | Non-covered Recipient Entity THE UROLOGY GROUP | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891793 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,721.00 | 02/21/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175256827 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $83.38 | 02/20/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401452 |
| Principal investigator 1 | COLOPLAST CORP | $1,747.57 | 02/13/2025 | Non-covered Recipient Entity The Urology Group | INTIBIA | No dispute reported | 06/30/2026 | 1226927240 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 02/12/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401462 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 02/12/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401478 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $71.98 | 02/12/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401532 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 02/12/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401534 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 02/10/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401480 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,460.00 | 02/10/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395647 |
| Principal investigator 1 | Eli Lilly and Company | $28,002.00 | 02/06/2025 | Non-covered Recipient Entity TRI STATE UROLOGIC SERVICES PSC INC | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) | No dispute reported | 06/30/2026 | 1187893764 |
| Principal investigator 1 | MEDIVATION LLC. | $1,056.00 | 02/06/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228855538 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,394.00 | 02/03/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175395615 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 02/03/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228841557 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 02/01/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228834572 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 02/01/2025 | Non-covered Recipient Entity The Urology Group | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228841611 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 01/31/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401538 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $232,664.36 | 01/29/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco | No dispute reported | 06/30/2026 | 1185548398 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $174,305.09 | 01/29/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185548400 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401488 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401522 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,212.00 | 01/29/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176625047 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,424.00 | 01/29/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176625074 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,810.00 | 01/28/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175257702 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $430.67 | 01/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401530 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,020.81 | 01/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401536 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 01/21/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175257032 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 01/21/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175257327 |
| Principal investigator 1 | Janssen Research & Development, LLC | $53,102.00 | 01/20/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175395776 |
| Principal investigator 1 | COLOPLAST CORP | $2,000.00 | 01/17/2025 | Non-covered Recipient Entity The Urology Group | INTIBIA | No dispute reported | 06/30/2026 | 1226927238 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,248.00 | 01/17/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175256898 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,574.00 | 01/17/2025 | Non-covered Recipient Entity Tristate Urologic Svcs Psc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175257385 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 01/13/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401464 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 01/13/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401466 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $130.00 | 01/13/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401476 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $425.00 | 01/13/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401512 |
| Principal investigator 1 | COLOPLAST CORP | $1,747.57 | 01/09/2025 | Non-covered Recipient Entity The Urology Group | INTIBIA | No dispute reported | 06/30/2026 | 1226927236 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,609.75 | 01/08/2025 | Non-covered Recipient Entity TriState Urologic Services PSC Inc. dba The Urology Group | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett | No dispute reported | 06/30/2026 | 1232924968 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $58.26 | 01/03/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401500 |
| Principal investigator 1 | MEDIVATION LLC. | $235.20 | 01/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228855590 |
| Principal investigator 1 | MEDIVATION LLC. | $235.20 | 01/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228856351 |
| Principal investigator 1 | MEDIVATION LLC. | $235.20 | 01/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228856429 |
| Principal investigator 1 | MEDIVATION LLC. | $1,056.00 | 01/02/2025 | Non-covered Recipient Entity TRISTATE UROLOGIC SERVICES PSC INC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228856480 |